Sharemaestro Newsreel

Zentalis Pharma Prices $80.5 Mln Offering Of Shares At $3.50 Per Share; Stock Down

(RTTNews) - Zentalis Pharmaceuticals, Inc. (ZNTL), a clinical-stage oncology company, priced a public offering of 23 million shares at $3.50 per share. The total gross proceeds from the offering are expected to be $80.5 million, and the company plans to use the net proceeds …

TG Therapeutics (TGTX) Raised Revenue Guidance After Q2, Is It Still Below Fair Value?

TG Therapeutics (TGTX) recently reported its Q2 2026 results, showing higher revenue, lower net income, and raised full-year revenue guidance to about US$950 million. Despite a recent 13% drop, the stock is up 64% year-to-date and is considered modestly undervalued at $47.94 against a …

Sol-Gel Technologies (SLGL) Projected to Announce Quarterly Earnings on Friday

Sol-Gel Technologies (SLGL) is expected to announce its Q2 2026 earnings before market open on Friday, August 21st, with analysts projecting a loss of $2.36 per share and revenue of $0.0750 million. This follows a previous quarter where the company reported a smaller loss …

Ladenburg Thalmann Initiates Turn Therapeutics(TTRX.US) With Buy Rating, Announces Target Price $16

Ladenburg Thalmann has initiated coverage on Turn Therapeutics (TTRX.US) with a "Buy" rating. The firm has also set a price target of $16 for the company's stock. This indicates a positive outlook from Ladenburg Thalmann regarding Turn Therapeutics' future performance.

ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlights: Zero ARIA-E Cases and Promising Biomarker Signals in Phase 1b Trial

ProMIS Neurosciences (PMN) reported strong Q2 2026 earnings call highlights, emphasizing zero ARIA-E cases and promising biomarker signals in its Phase 1b PRECISE-AD trial. The company maintains a strong cash position of $53.4 million, funding operations through 2027, and is advancing its pipeline candidates …

Alterity Therapeutics Quotes 354,203 Ordinary Shares Following Option Exercise

Alterity Therapeutics Limited (ASX:ATH) has applied for the quotation of 354,203 new ordinary shares on the ASX, which were issued on August 14, 2026, after the exercise of options under the security code ATHO. These options were exercised at AUD $0.50 per security and …

EyePoint (EYPT) Is Up 5.1% After Steep Q2 Revenue Drop And ESOP-Linked Share Offering Filing

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most

Relmada (RLMD) Q2 2026 Earnings Call Transcript

Karyopharm Q2 Net Loss Expands; Reaffirms 2026 Revenue Guidance; Plans SNDA For Selinexor In August

(RTTNews) - Karyopharm Therapeutics Inc. (KPTI), a commercial-stage pharmaceutical company, reported financial results for the second quarter of 2026, reflecting a wider net loss and provided an update on the company's myelofibrosis program. In addition, the company reaffirmed the full-year 2026 revenue guidance. Karyopharm, …

Capricor Therapeutics (CAPR) Shares Soar Over 67% After Hours: Here's Why

CNH Industrial Posts Upbeat Q2 Earnings, Joins Autolus Therapeutics, Bowhead Specialty Holdings And Other Big Stocks Moving Higher On Monday

CNH Industrial (NYSE: CNH) shares surged after reporting better-than-expected Q2 earnings and raising its FY26 adjusted EPS guidance. Several other stocks, including Atkore Inc (NYSE: ATKR), Autolus Therapeutics PLC (NASDAQ: AUTL), and Newell Brands Inc (NASDAQ: NWL), also saw significant gains following positive financial …

Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update

Alpha Cognition Inc. announced its second-quarter 2026 financial results, highlighting a significant 71% quarter-over-quarter increase in ZUNVEYL net product revenue to $6.0 million and a 37% rise in bottles dispensed. The company also reported expanding prescriber base and penetration in long-term care facilities, alongside …

Earnings call transcript: Alpha Cognition posts strong Q2 2026 sales growth

Alpha Cognition (NASDAQ: ACOG) announced strong Q2 2026 results, with ZUNVEYL net product revenue rising 71% sequentially to $6.0 million and total revenue increasing 258% year-over-year. The company narrowed its net loss and cut full-year operating expense guidance, demonstrating commercial momentum for its Alzheimer’s …

Summit Therapeutics (SMMT) Expands Ivonescimab Reach As Investors Ask If The Story Is Priced In

Cibus Inc (CBUS) (Q2 2026) Earnings Call Highlights: Strategic P

Turn Therapeutics (NASDAQ:TTRX) Stock Price Down 6.5% - Time to Sell?

ATAI Beckley earnings beat by $0.03, revenue topped estimates

Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update

Gossamer Bio announced its Q2 2026 financial results and provided a business update, highlighting its progress toward an NDA submission for seralutinib in PAH by September 2026. The company reacquired worldwide development and commercial rights for seralutinib and significantly reduced its debt through a …

Veru 3Q Loss $6.99M >VERU

This article reports that Veru (VERU) experienced a third-quarter loss of $6.99 million. The brief financial update indicates the company's performance for the recent fiscal period.

Is Vera Therapeutics (VERA) Undervalued On FDA Approval For TRUTAKNA?

Vera Therapeutics (VERA) received accelerated FDA approval for TRUTAKNA for IgA nephropathy, but its share price has fallen recently despite strong long-term returns. The company is currently loss-making and trades at a P/B ratio of 5.4x, which is below peers but above the broader …

Form 8K EDESA BIOTECH For: 13 August By Investing.com

This article reports that EDESA BIOTECH filed a Form 8K on August 13th, as tracked by Investing.com. The filing details are not provided within the article itself, but it highlights the company EDSA with a stock performance of +2.45%. The piece is primarily a …

Moderna (MRNA): Buy, Sell, or Hold Post Q2 Earnings?

Despite a recent 44.2% surge in Moderna's stock price, StockStory advises against investing in the company due to declining revenue and EPS over the last five years, and a negative free cash flow margin. The analysis suggests Moderna is a low-quality business, with the …

Renaissance Technologies (CORT) discloses 4.90% beneficial stake in Corcept Therapeutics

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a beneficial ownership of 4.90% in Corcept Therapeutics Inc., amounting to 5,261,628 shares of common stock. This Schedule 13G/A filing indicates that Renaissance Technologies holds sole voting and dispositive power over these shares. Certain …

MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Investor Relations - Stefanie Perna-NacarPresident and Chief Executive Officer - Jennifer BuellHead of Development - Terese HammondPrincipal Financial Officer - Melissa Orilall TAKEAWAYS Cash and Cash Equivalents -- …

Nektar outlines REZPEG Phase III timeline with mid-2028 data and 2029 BLA plan

Earnings Call Insights: Nektar Therapeutics (NKTR) Q2 2026 MANAGEMENT VIEW * “In July, we achieved yet another important milestone in Nektar with the initiation of the global ZENITH AD program, Phase III AD program for rezpegaldesleukin” (CEO, President & Director Howard W. Robin). “With …

MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates

MediciNova (MNOV) reported a Q2 loss of $0.05 per share, surpassing the Zacks Consensus Estimate of a $0.06 loss and improving from a $0.07 loss a year ago. The company also exceeded revenue estimates, posting $0.46 million against a $0.15 million consensus, though its …

Ken Takanashi Sells 3,864 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock

WAVE Life Sciences (NASDAQ:WVE) Director Adrian Rawcliffe Sells 12,700 Shares

WAVE Life Sciences (NASDAQ:WVE) Director Adrian Rawcliffe sold 12,700 shares of the company's stock for approximately $67,183. The sale occurred on August 12th when shares were trading at $5.29. Following the transaction, WVE shares fell to $5.20, near their 12-month low, and the company …

Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Director Sells $42,070.00 in Stock

WAVE Life Sciences (NASDAQ:WVE) Director Heidi Wagner sold 7,000 shares of the company's stock for $42,070, reducing her position by 13.48%. The sale occurred amidst weak trading and quarterly results, with WVE shares near their 52-week low and the company reporting a loss and …

Parabilis Medicines (PBLS) Earnings Date and Reports 2026

Alnylam Pharmaceuticals (ALNY) Cuts Guidance As Undervalued Narrative Faces A Tougher Test

Alnylam Pharmaceuticals (ALNY) recently cut its full-year 2026 TTR product sales guidance by $200 million and is under a securities law investigation, causing its stock price to drop significantly. Despite a current "undervalued" narrative with a fair value of $434.72 against its $227.12 close, …

Barclays Maintains Forte Biosciences(FBRX.US) With Hold Rating, Maintains Target Price $77

Barclays has reiterated its 'Hold' rating on Forte Biosciences (FBRX.US) and maintained its target price at $77. This indicates that the financial institution sees the stock performing in line with the broader market and expects its value to remain stable at the specified price …

Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX)

Levi & Korsinsky has announced an investigation into Ardelyx (ARDX) following a significant 17.86% stock drop on August 7, 2026. This decline occurred after the company reported second-quarter 2026 product revenue and earnings per share that were below consensus estimates, and subsequently lowered its …

Farallon funds report 10.28M-share, 9.99% Beam Therapeutics (BEAM) position

Farallon Capital Management and its affiliated funds have disclosed a beneficial ownership of 10,282,210 shares of Beam Therapeutics (BEAM) common stock, representing 9.99% of the outstanding class. This position includes directly held shares and common stock purchase warrants, with exercisability capped at 9.99% due …

XBiotech (NASDAQ:XBIT) Issues Quarterly Earnings Results, Misses Estimates By $0.25 EPS